WHO enlists Bangladesh's Globe Biotech's Covid-19 vaccine
Published : Saturday, 17 October, 2020 at 6:53 PM Count : 463
The World Health Organization (WHO) has enlisted the Covid-19 vaccine developed by Bangladeshi pharmaceuticals company Globe Biotech.
Globe Biotech's vaccine was listed in the WHO's draft landscape of Covid-19 candidate vaccines on October 15.
Dr Kakon Nag, Globe Biotech's chief executive officer told said, "It's a matter of immense pride for all Bangladeshis to have the Globe Biotech's vaccine listed on the WHO website. Because the name that came is Globe Biotech Limited, Bangladesh. This is the first time we have seen the name of Bangladesh in the WHO list for the discovery of the vaccine."
Asked when they would apply to the BMRC for the Globe Vaccine Human Trial, Dr Kakon Nag said, "In this regard our CRO are working on their own. They will apply to the BMRC for the Human Trial when they reach the milestone. We hope to finish everything quickly and apply for trial."
In a press release, Globe Biotech said, they are the only company in the world to be listed with three vaccine candidates - DNA plasmid vaccine, Adenovirus Type 5 Vector and D614G variant LNP-encapsulated mRNA.
Earlier, the International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b) said it will hold a human trial of BANCOVID, a Covid-19 vaccine developed by Globe Biotech.
icddr,b will now seek permission from the Bangladesh Medical Research Council (BMRC) to conduct the trial, officials said.
On Wednesday, icddr,b signed a memorandum of understanding with the company to conduct the human trial.
On 2 July, Globe Biotech announced they were developing a Covid-19 vaccine as they had completed preliminary animal trials successfully.
On October 5, they said they had received "very promising" results from the pre-clinical trials on rabbits and mice.
The company said BANCOVID would hit the market in late December or early January next year if the government was fully supportive.